Preclinical and Phase 1 Assessment of Antisense Oligonucleotide Bepirovirsen in Hepatitis B Virus–Transgenic Mice and Healthy Human Volunteers: Support for Clinical Dose Selection and Evaluation of Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses

Dose‐dependent reductions in hepatitis B virus (HBV) RNA, DNA, and viral proteins following bepirovirsen administration were observed in HepG2.2.15 cells. In HBV‐transgenic mice treated at 50 mg/kg/wk, hepatic HBV RNA and DNA were reduced by 90% and 99%, respectively. Subsequently, a phase 1 first‐i...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Kelong, Theodore, Dickens, McMullen, Gina, Swayze, Eric, McCaleb, Michael, Billioud, Gaetan, Wieland, Stefan, Hood, Steve, Paff, Melanie, Bennett, C. Frank, Kwoh, T. Jesse
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804925/
https://www.ncbi.nlm.nih.gov/pubmed/35971951
http://dx.doi.org/10.1002/cpdd.1154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804925/
https://www.ncbi.nlm.nih.gov/pubmed/35971951
http://dx.doi.org/10.1002/cpdd.1154

Ejemplares similares